Drugs / Priorix
Priorix
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT02861586 | Aug 2016 → Sep 2017 | chikungunya | Themis Bioscience GmbH | Completed | No outcome recorded |
| Phase 2 | NCT00861744 | Jun 2009 → Jul 2010 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00353288 | Mar → Nov 2006 | measles, mumps infectious disease, rubella, varicella zoster infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 38 trials · 3 met primary | ||||||
| Phase 3 | NCT02184572 | Aug 2014 → Aug 2015 | primary viral infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02058563 | Jul 2014 → May 2015 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT01702428 | Nov 2012 → Nov 2014 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01681992 | Oct 2012 → Feb 2015 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | Mixed |
| Phase 3 | NCT01621802 | Jun 2012 → Jul 2015 | viral infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00969436 | Nov 2009 → Feb 2011 | measles, mumps infectious disease, rubella, varicella zoster infection | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00226499 | Sep 2005 → Oct 2006 | chickenpox | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00406211 | Jul → Dec 2004 | chickenpox, measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02325310 | Feb 2015 → May 2016 | measles, mumps infectious disease, rubella | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT00388440 | Nov 2000 → Apr 2001 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 3 | NCT06855160 Background | Apr 2025 → Sep 2026 overdue | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06824181 Background | Feb 2025 → Sep 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06824194 Background | Feb 2025 → Oct 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06399003 Comparator | Jun → Sep 2024 | primary viral infectious disease | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
| Phase 3 | NCT02173704 Comparator | Sep 2014 → Dec 2015 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01627561 Comparator | Oct 2012 → Apr 2014 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01245049 Background | Apr 2011 → Mar 2012 | diphtheria, poliomyelitis, tetanus | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00326118 Background | Jun 2006 → Nov 2007 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02002156 Background | Jun 2014 → Aug 2016 | tuberculosis | University of Oxford | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-06-06 | GlaxoSmithKline | Regulatory GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older gsk.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-06-06 | GlaxoSmithKline | GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older gsk.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Priorix | “A Phase 3a, Open-Label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and...” NCT06855160 ↗21“Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.” NCT02173704 ↗ “Measles-mumps-rubella Vaccine (Priorix™) Co-administered With Varicella Vaccine (Varilrix™)” NCT00353288 ↗ “one dose of Priorix investigational vaccine (Lot 1) subcutaneously in the right upper arm” NCT00861744 ↗ |
| Known as | Combined measles-mumps-rubella (MMR) vaccine | “Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®” NCT02325310 ↗ |
| Known as | GSK MMR Vaccine | “Biological: GSK MMR Vaccine (PRIORIX)” NCT06399003 ↗ |
| Known as | Measles-mumps-rubella Vaccine | “Measles-mumps-rubella Vaccine (Priorix™)” NCT00353288 ↗ |
| Known as | MMR | “MMR (Priorix®)” NCT00406211 ↗ |
| Known as | MMR-RIT | “This phase III, observer-blind, randomized controlled trial (NCT02058563) assessed the immunogenicity and safety of a dose of the MMR-RIT vaccine (Priorix, GSK) compared to MMR...” PMID 29902133 ↗ Jul 20181“Priorix™ [MMR-RIT, GSK, Belgium]” PMID 28481690 ↗ May 2017 |
| Known as | Priorix, GlaxoSmithKline UK | “Priorix®, GlaxoSmithKline UK” NCT02002156 ↗ |
| Modality | Vaccine | “measles-mumps-rubella vaccine” PMID 33736915 ↗ Mar 2021 |
| Route | Subcutaneous | “administered subcutaneously” NCT00226499 ↗ |